Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

After a 2024 marred by a series of trial failures, Sage Therapeutics Inc. (Nasdaq ... approved for postpartum depression, in partnership with Biogen. Zurzuvae was approved by the FDA in August ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for depression and neurological disorders. The licensing agreement gives Biogen ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

Biogen has made an unsolicited offer to acquire its partner Sage Therapeutics following ... in August 2023 as the first oral treatment for postpartum depression (PPD). While the news was welcomed ...

Biogen offers $7.22 per share to acquire Sage Therapeutics. Goldman Sachs projects ... success of the Zurzuvae launch for postpartum depression (PPD). Biogen says Zurzuvae exceeded its expectations.

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...